Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences presented two-year data from the Phase 3 CAHtalyst Adult study, showing that treatment with CRENESSITY enabled sustained glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia. At Month 24, 69% of participants achieved physiologic-range glucocorticoid dosing with a mean 38% reduction from baseline, while maintaining androgen control.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Phase Of Trial
- Phase 3
- Mean gc reduction percent
- -38%
- Study retention two years
- >80%
- Physiologic dose achievement 24mo
- 69%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.